Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH Sensitivity in Prader-Willi Syndrome
NCT01298180Phase 4Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jan 2009
- Primary completion
- May 2013
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, open-label trial of somatropin in Prader-Willi syndrome (PWS) and growth hormone deficiency (GHD) (5 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Circulating rates of IGF-I at 1 year. Started Jan 2009; status: completed.
02
Drugs
somatropin
03
Conditions
Prader-Willi syndrome (PWS)growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT01298180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01298180.